Table 2.
Costs, effects and incremental cost-effectiveness ratios of all treatment options for idiopathic pulmonary fibrosis compared with placebo.
| Cost ($) | Quality-adjusted life year |
Disability-adjusted life year |
Mortality |
||||
|---|---|---|---|---|---|---|---|
| Effect | ICER ($/QALY) | Effect | ICER ($/DALY) | Effect | ICER ($/Death) | ||
| Ambrisentan | 1,390,709 | 12.12 | 351,083 | 12.43 | 338,887 | 14.81 | 281,591 |
| Bosentan | 3,731,536 | 15.10 | 539,526 | 14.81 | 578,244 | 17.87 | 468,589 |
| Imatinib | 8,441,770 | 15.16 | 1,214,542 | 15.49 | 1,187,133 | 17.87 | 1,064,068 |
| NAC | 171,199 | 12.46 | 34,564 | 13.21 | 30,396 | 14.81 | 30,145 |
| NAC + pirfenidone | 541,889 | 15.25 | 73,632 | 15.50 | 72,802 | 18.36 | 61,535 |
| Nintedanib | 1,523,262 | 14.29 | 247,239 | 14.13 | 261,478 | 17.39 | 201,651 |
| Sildenafil + nintedanib | 1,645,400 | 10.48 | 720,180 | 10.73 | 695,453 | 12.69 | 593,555 |
| Pirfenidone | 339,890 | 12.97 | 66,434 | 13.58 | 60,791 | 15.61 | 55,734 |
| Sildenafil | 449,460 | 9.31 | 393,023 | 9.99 | 266,959 | 10.95 | 428,753 |
Abbreviations: NAC, N-acetylcysteine; ICER, Incremental cost-effectiveness ratio; QALY, Quality-adjusted life year; DALY, Disability-adjusted life year.